Moderna announced Tuesday that its COVID-19 vaccine is highly effective in protecting younger teenagers against coronavirus and poses no safety concerns.
The shot had an efficacy of 100% against symptomatic COVID in adolescents after two doses in its clinical trial, according to the press release.
[Ads /]
The company said it plans to ask the Food and Drug Administration for emergency use authorization for 12- to 17-year-olds in early June.
Moderna's and Johnson & Johnson's vaccines are currently authorized in the U.S. for 18-years-old and older, while Pfizer's was greenlit for younger teens earlier this month.